Evidence map›Paper›PMID 40487556›Full record

ArticleCase reports in oncology

Enfortumab Vedotin-Induced Diabetic Ketoacidosis and Acute Tubulointerstitial Nephritis Requiring Intensive Care in the Treatment of Advanced Urothelial Carcinoma: A Case Report.

Ryo Matsui, Yoshihide Kawasaki, Yohei Satake, Kei Takahashi, Satoko Kurosawa, Tomonori Sato, Hiromichi Katayama, Takuma Sato, Naoki Kawamorita, Shinichi Yamashita and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ryo MatsuiDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yoshihide KawasakiDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yohei SatakeDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kei TakahashiDepartment of Diabetes, Metabolism and Endocrinology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Satoko KurosawaDepartment of Diabetes, Metabolism and Endocrinology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tomonori SatoDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Hiromichi KatayamaDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Takuma SatoDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Naoki KawamoritaDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Shinichi YamashitaDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Hideki KatagiriDepartment of Diabetes, Metabolism and Endocrinology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Akihiro ItoDepartment of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Enfortumab vedotin (EV) has been approved for the treatment of many types of cancer, and its use is still expanding. It is an essential drug used as a standard treatment for advanced and metastatic urothelial carcinoma but is known to cause various adverse events (AEs). Case Presentation: We report a patient with metastatic urothelial carcinoma who experienced multiple AEs associated with diabetic ketoacidosis (DKA) during EV treatment. The onset of DKA during EV treatment has been reported to be associated with poor prognosis. Although strict management was required in the intensive care unit, we were able to save the patient's life. Conclusion: Although the detailed mechanism that induced insulin resistance remains unclear, the patient required high-dose insulin because of a marked increase in insulin resistance. If hyperglycemia is observed during EV therapy, DKA may lead to the occurrence of serious AEs. We report on the pathogenesis and management of drug-induced DKA caused by EV based on our case and a literature review.

Indexed as

Advanced urothelial carcinomaDiabetic ketoacidosisEnfortumab vedotinInsulinIntensive care

Identifiers

PMID40487556
PMCPMC12143863

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.